Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 162

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Agalsidase Alfa and Kidney Dysfunction in Fabry Disease

Open access
West, Michael, Nicholls, Kathy, Mehta, Atul, Clarke, Joe T.R., Steiner, Robert, Beck, Michael, Barshop, Bruce A., Rhead, William, Mensah, Robert, Ries, Markus, Schiffmann, Raphael · 2009 · Journal of the American Society of Nephrology

Abstract

In male patients with Fabry disease, an X-linked disorder of glycosphingolipid metabolism caused by deficient activity of the lysosomal enzyme alpha-galactosidase A, kidney dysfunction becomes apparent by the third decade of life and invariably progresses to ESRD without treatment. Here, we summarize the effects of agalsidase alfa on kidney function from three prospective, randomized, placebo-controlled trials and their open-label extension studies involving 108 adult male patients. The mean baseline GFR among 54 nonhyperfiltrating patients (measured GFR <135 ml/min per 1.73 m(2)) treated with placebo was 85.4 +/- 29.6 ml/min per 1.73 m(2); during 6 mo of placebo, the mean annualized rate of change in GFR was -7.0 +/- 32.9 ml/min per 1.73 m(2). Among 85 nonhyperfiltrating patients treated with agalsidase alfa, the annualized rate of change was -2.9 +/- 8.7 ml/min per 1.73 m(2). Treatment with agalsidase alfa did not affect proteinuria. Multivariate analysis revealed that GFR and proteinuria category (< 1 or > or = 1 g/d) at baseline significantly predicted the rate of decline of GFR during treatment. This summary represents the largest group of male patients who had Fabry disease and for whom the effects of enzyme replacement therapy on kidney function have been studied. These data suggest that agalsidase alfa may stabilize kidney function in these patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1681/asn.2008080870

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 162

Metadata

Authors
West, M., Nicholls, K., Mehta, A., Clarke, J. T. R., Steiner, R., Beck, M., Barshop, B. A., Rhead, W., Mensah, R., Ries, M., & Schiffmann, R.
Venue
Journal of the American Society of Nephrology
Published
2009-05
Volume
20
Issue
5
Pages
1132-1139
ISSN
1046-6673 (ISSN-L)
OpenAlex
W2101510401
Cited by
162
References
1
FWCI
12.99
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Agalsidase Alfa and Kidney Dysfunction in Fabry Disease. https://app.cochat.ai/papers/10.1681/asn.2008080870
The paper
West, M., Nicholls, K., Mehta, A., Clarke, J. T. R., Steiner, R., Beck, M., Barshop, B. A., Rhead, W., Mensah, R., Ries, M., & Schiffmann, R. (2009). Agalsidase Alfa and Kidney Dysfunction in Fabry Disease. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.2008080870

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.